NCT04655482 - Treat-and-extend Using Aflibercept for Type 3 Neovascularization | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

December 20, 2023

Study Completion Date

August 20, 2024

Conditions

Retinal Angiomatous Proliferation

Interventions

DRUG

Aflibercept Injection

"Intravitreal injection of aflibercept using treat-and-extend regimen~:Three monthly loading injections followed by proactive treatment using TAE regimen. Extension of injection interval by 2 weeks. The maximum injection interval was set as 16 weeks."

Trial Locations (1)

150-034

RECRUITING

Jae Hui Kim, Seoul